RPRX - Company ID 0001802768
Royalty Pharma plc trades as RPRX and has a market capitalization of $21.16 B, making it the #607 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.38B, up 5.1% from the prior year and net income of $770.95M. This page tracks Royalty Pharma plc through 588 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-06-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years Royalty Pharma plc's revenue grew from $1.79B to $2.38B, a compound annual growth rate of 4.1%. Net profit margin compressed from 76.8% to 32.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-15 |
| Insider trade | 4 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider sale notice | 144 | 2026-05-14 |
| 13F-NT | - | 2026-05-14 |
| SCHEDULE 13G/A | - | 2026-05-14 |
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
Royalty Pharma Declares Second Quarter 2026 Dividend
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
The largest companies sharing Royalty Pharma plc's SEC industry classification (pharmaceutical preparations).
Royalty Pharma plc (RPRX) has a market capitalization of $21.16 B as of 2026-06-10, ranking #607 among US-listed companies.
Royalty Pharma plc reported revenue of $2.38B for fiscal year 2025, an increase of 5.1% year over year.
Yes. Royalty Pharma plc reported net income of $770.95M in its latest fiscal year.